CD8A and neoplasm: We assessed the mechanism of tumor rejection by αCD45-Cyt therapy through antibody depletions and knockout mice: αCD45-Cyt therapy entirely depended on CD8+ T cells and batf3+ dendritic cells, consistent with a critical role for tumor antigen crosspresentation (Fig. 3b).